From: Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance
Clinical findings | Frequency | Percent |
---|---|---|
Site of tumor | Â | Â |
 Tongue | 13 | 28.3 |
 Buccal Mucosa | 24 | 52.2 |
 Lower Alveolus | 6 | 13.0 |
 Upper Alveolus | 1 | 2.20 |
 Lip | 2 | 4.30 |
Side | Â | Â |
 Right | 18 | 39.1 |
 Left | 26 | 56.5 |
 Midline | 1 | 2.20 |
 Crossing midline | 1 | 2.20 |
Number lesion | Â | Â |
 Single | 44 | 95.70 |
 Multiple | 2 | 4.30 |
Clinical size of tumor (cm)* | Â | Â |
 ≥ 4 | 19 | 41.30 |
 < 4 | 27 | 58.70 |
Extension to adjacent site | Â | Â |
 Yes | 17 | 37 |
 No | 29 | 63 |
T status | Â | Â |
 T2 | 23 | 50.00 |
 T3 | 8 | 17.40 |
 T4 | 15 | 32.60 |
Clinical nodes | Â | Â |
 No | 15 | 32.60 |
 N1 | 17 | 37.00 |
 N2 | 13 | 28.30 |
 N3 | 1 | 2.20 |
Stage | Â | Â |
 II | 17 | 37.00 |
 III | 11 | 23.90 |
 IVa | 17 | 37.00 |
 IVb | 1 | 2.20 |
Comorbid factors | Â | Â |
 Yes | 8 | 17.40 |
 No | 38 | 82.60 |
ECOG performance status | Â | Â |
 0 | 9 | 19.60 |
 1 | 37 | 80.40 |
Imaging | ||
 CT size (cm) |  |  |
  < 4 | 13 | 28.30 |
  ≥ 4 | 33 | 71.70 |
Neck node present | 22 | 47.80 |
 Involved adjacent site |  |  |
  Bone | 9 | 19.60 |
  Skin | 5 | 10.90 |
  Muscle | 9 | 19.60 |
TNM stage (CT) | Â | Â |
 II | 11 | 23.90 |
 III | 17 | 37.00 |
 IVa | 17 | 37.00 |
 IVb | 1 | 2.00 |
Neck dissection | ||
 SOHND | 22 | 47.80 |
 MRND | 17 | 37.00 |
 None | 7 | 15.20 |
Surgical reconstruction | ||
 None | 16 | 34.80 |
 Pectoralis major myocutaneous flap | 14 | 30.40 |
 Nasolabial flap | 13 | 28.30 |
 Buccal pad of fat | 2 | 4.30 |
 Sternocleidomastoid flap | 1 | 2.20 |
 Total | 46 | 100.0 |
Histopathological findings | ||
 HPE grade |  |  |
  I (well differentiated) | 22 | 47.80 |
  II (moderately differentiated) | 22 | 47.80 |
  III (poorly differentiated) | 2 | 4.30 |
T size (cm) | Â | Â |
 ≥ 4 | 11 | 23.90 |
 < 4 | 35 | 76.10 |
Positive margin | 2 | 4.30 |
Lymphovascular invasion | 13 | 28.30 |
Perineural invasion | 20 | 43.50 |
Depth of invasion (mm) | Â | Â |
 < 5 | 4 | 8.70 |
 ≥ 5 to < 10 | 24 | 52.20 |
 ≥ 10 | 18 | 39.10 |
Pathological stage | Â | Â |
 I | 1 | 2.20 |
 II | 22 | 47.80 |
 III | 7 | 15.20 |
 IVa | 13 | 28.30 |
 IVb | 3 | 6.50 |
Mutations | ||
 TP53 | 19 | 41.3 |
 CDKN2A | 11 | 23.9 |
 HRAS | 8 | 17.4 |
 PIK3CA | 3 | 6.5 |
 SMARCB1 | 2 | 4.3 |
 KIT | 1 | 2.2 |
 EGFR | 1 | 2.2 |
 BRAF | 1 | 2.2 |
 STK11 | 1 | 2.2 |
 ABL1 | 1 | 2.2 |
 RB1 | 1 | 2.2 |
 NRAS | 0 | 0.0 |
 KRAS | 0 | 0.0 |